Pfizer steps up race for weight-loss drug
Pfizer plans to discontinue its obesity drug lotiglipron and focus instead on its weight loss drug danuglipron as it races to rival the success of other weight loss treatments.
Subscribe to:
Post Comments (Atom)
Comments
Post a Comment
Leave a comment. Thanks!
Comentarios de Facebook